OR WAIT 15 SECS
Consort Medical announced that it has agreed terms to acquire the entire issued and to be issued share capital of Aesica Pharmaceuticals for £230 million.
Consort Medical announced that it has agreed terms to acquire the entire issued and to be issued share capital of Aesica Pharmaceuticals for £230 million. The closing of the transaction, which is expected to occur in November, is conditional on the approval of Consort Medical’s shareholders and clearance by the German competition authorities.
Consort Medical, a UK company listed on the London Stock Exchange, specializes in the development and manufacturing of disposable medical devices for drug delivery including inhaled, nasal and injectables products through its core operating division Bespak.
CDMO Aesica provides contract development and manufacturing services for finished dose and APIs to the global pharmaceutical industry. Since its establishment in 2004, Aesica has grown both organically and through acquisitions and has established key strategic relationships with major global blue-chip pharmaceutical companies.